Dr Hwang reviews key findings of research he presented at ACR Convergence on inflammatory back pain and the importance of multimodality evaluation to identify patients with axial spondyloarthritis vs mechanical back pain.
Dr Hwang reviews key findings of research he presented at ACR Convergence on inflammatory back pain and the importance of multimodality evaluation to identify patients with axial spondyloarthritis vs mechanical back pain.
An 8-week individualized training program led to significant improvements in trunk function and aerobic capacity in patients with axSpA, offering rheumatologists new data to support exercise-based interventions.
An 8-week individualized training program led to significant improvements in trunk function and aerobic capacity in patients with axSpA, offering rheumatologists new data to support exercise-based interventions.
A phase III randomized trial showed QX002N significantly improved clinical outcomes and MRI-assessed inflammation in patients with radiographic axSpA, with a favorable safety profile.
A phase III randomized trial showed QX002N significantly improved clinical outcomes and MRI-assessed inflammation in patients with radiographic axSpA, with a favorable safety profile.
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
Dr Karmacharya reviews his presentation from ACR Convergence a population-based study from the UK THIN database across psoriatic arthritis, psoriasis, and axial spondyloarthritis to find distinct and remarkably stable patterns of...
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
